No Link to Femur Fractures Found with Bisphosphonates
By John Gever, Senior Editor, MedPage Today Published: March 24, 2010 Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and Dorothy Caputo, MA, RN, BC-ADM, CDE, Nurse Planner Atypical femoral fractures in patients with osteoporosis were extremely rare and not significantly more common with bisphosphonates, results of a meta-analysis showed. Among more than 14,000 patients involved in three large randomized trials, only 12 fractures of the subtrochanteric or diaphyseal femur were recorded, Dennis Black, PhD, of the University of California San Francisco, and colleagues reported online in the New England Journal of Medicine. The investigators looked at data from the Fracture Intervention Trial (FIT) and its five-year extension, which compared alendronate (Fosamax) to placebo, and the HORIZON Pivotal Fracture Trial, which tested zoledronic acid (Reclast). They reported the following relative risks for subtrochanteric or d...